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Multiple sclerosis (MS) is a progressive inﬂammatory and demyelinating disease that aﬀects more than 2.5 million people
worldwide every year. Current therapies use mostly disease-modifying drugs, focusing on blocking and regulating systemic
functions and the central nervous system (CNS) inﬁltration of immune cells; however, these therapies only attenuate or delay MS
symptoms,but are noteﬀective in haltingthe diseaseprogression.More recent evidence indicated thatregulation ofinﬂammation
within the CNS might be a better way to approach the treatment of the disease and microglia, the resident immune cells, may be a
promisingtarget of therapeutic studies. Microglia activation classicallyaccompaniesMS development,and regulation ofmicroglia
function changes the outcome of the disease. In this paper, we review the contributions of microglia to MS pathogenesis and
discuss microglial functions in antigen presentation, cytokine release, and phagocytosis. We describe data both from animal and
human studies. The signiﬁcant impact of the timing, intensity, and diﬀerentiation fate of activated microglia is discussed, as they
can modulate MS outcomes and potentially be critically modiﬁed for future therapeutic studies.
1.Background
Multiple sclerosis (MS) is a progressive autoimmune inﬂam-
matory and demyelinating disease of the central nervous
system (CNS). The pathological hallmarks of MS are white
matter demyelination, inﬂammation, axon damage, and
blood-brain barrier (BBB) disruption [1–3]. The etiology of
MS is still not clear, but MS is classically characterized by
proinﬂammatory T helper (Th) cells, Th1 and Th17 inﬁl-
tration into the CNS [1, 4]. However, a large number of
studies suggested that MS may be initiated within the CNS
in the absence of peripheral immune cell inﬁltration [5, 6].
Axon injury has been observed and reported very early
duringthedevelopmentofMS,independentlyoflymphocyte
inﬁltration and myelin damage [7, 8]. Oligodendrocyte(OL)
apoptosis and microglia activation have been observed in
MS specimens that did not yet show lymphocytic inﬁltration
[6, 9]. Furthermore, MS is known to be attributed to viral
infections, genetic background,and environment factors [2].
Therefore, MSmay benotonedisease, butrathera collection
of diﬀerent syndromes presenting themselves with inﬂam-
mation and demyelination and multiple mechanisms under-
lying the etiology of the disease.
Because of the complex etiology of MS, it is hard to de-
velop a single animal model to exactly mimic the condition
and symptoms of MS patients. Several animal models have
been developed in diﬀerent animal species to focus on dif-
ferent aspects of the disease. Experimental autoimmune
encephalomyelitis (EAE) is the most commonly used model
for MS. It is induced by immunization of mice and rats,
primarily, with myelin antigens including myelin oligoden-
drocyte glycoprotein (MOG), myelin basic protein (MBP),
a n dp r o t e o l i p i dp r o t e i n( P L P )[ 10]. The immunization is
either active (administration of the speciﬁc antigens) or
passive (administration of myelin-speciﬁc T cells). Several
MS features are recapitulated by EAE, including paralysis,
weight loss, demyelination, and inﬂammation in the CNS.In
the EAE model, activated myelin-speciﬁc T cells, mainly Th1
and Th17 cells, contribute to the compromise of the BBB
and migrate into the CNS. In the CNS, inﬁltrating and local2 Neurology Research International
antigen presenting cells (APCs) present antigens to reactive
T cells, leading to further inﬂammation, demyelination, and
axon damage [1, 4, 10]. However, the symptoms and animal
susceptibility of EAE depend on the types of immunizing
antigens and strains or species of animals used. Not all
myelin antigens work in every rodent strain, and diﬀerent
combinations may induce animal models reﬂecting diﬀerent
subtypes and clinical course of MS. H-2U mice, especially
the PL/J strains, are highly susceptible to MBP-induced EAE.
SJL mice are susceptible to PLP-induced EAE and result
in a remitting-relapsing EAE course. However, the most
commonly used strain is the C57BL/6(B6) mice, as many
transgenic and knockout animals are maintained on this
genetic background. The C57BL/6 mice are not susceptible
to MBP-induced EAE; they develop symptoms only after
immunization with MOG. They can exhibit either mild/
transient or severe/chronic phages depending on dosage of
myelin components and immunization times [11]. For rat
EAE, the most commonly used strain is the Lewis rats that
are sensitive to both MBP and MOG-induced disease.
Theiler’s murine encephalomyelitis virus-induced demy-
elinating disease (TMEV-IDD) is another inﬂammatory
model of MS. Diﬀerent from EAE, TMEV-IDD is initiated
by virus infection. Responses from immune cells in this
model, such as the cell types that react and the timing of
reaction, may diﬀer from EAE [12, 13]. Along similar lines,
subcutaneous injection of BCG (bacillus Calmette-Gu´ erin)
has been shown to induce a delayed-type hypersensitivity
(DTH)responseaccompaniedbyinﬁltrationofmacrophages
and lymphocytes, the breakdown of the blood–brain barrier
and immunoreactive myelin loss [14].
There are other models that induce chemical injury, such
as cuprizone, lysolecithin and ethidium bromide, and result
in focal demyelination in the white matter. These models
are valued for studying the mechanism of demyelination/
remyelination (as remyelination is initiated upon termina-
tion of the chemical injury reagent), butthey cannot account
for the whole picture of MS, because they are devoid of
a massive leukocyte inﬁltration [13, 15, 16]. Compared to
these models, EAE, even though it has the drawback that
the disease onset is speciﬁcally due to a deﬁned antigen
presentation as opposed to MS, appears to relatively better
reﬂect and recapitulate critical features and progressions of
MS; therefore, most of the current mechanism studies and
treatments for MS still mainly rely on EAE models [17].
Current therapiesfocusonblocking/regulatingfunctions
andCNSinﬁltration ofperipheral immunecells. Application
of interferon-β (IFN-β), glucocorticoids (GCs), and glati-
ramer acetate have been shown to be eﬀective in slowing or
delaying disease progression. However, no therapy has been
shown to stop long-term progression, or to cure the disease
[18, 19]. One of the drawbacks is that these therapies induce
a systemic inhibition of inﬂammation, which may block
beneﬁcial impacts of inﬂammation and impair recovery.
Moreover, with nonspeciﬁc inhibition, the risk ofdeveloping
other adverse events, such as cancer, is increased [20, 21].
Most importantly, it is still not clear what the real initiator
of the disease is, inﬂammation in the periphery, or damage
in the CNS. Inhibiting or regulating inﬂammation may
superﬁcially alleviate part of symptoms, yet does not really
solve the problem.
Therefore, it may be wiser to target the local immuno-
modulation through enhancing the beneﬁcial aspects of
inﬂammation withintheCNS,and atthesame timepromote
recovery by triggering and stimulating endogenous neural
cells including halting death of OLs and neurons and induc-
ing oligogenesis by neural stem cells (NSCs). However, for
thisgoaltobeaccomplished,acomprehensiveunderstanding
of the interaction between CNS and periphery immune
system is required, as well as understanding the interaction
betweenneuralcellsandimmunecells,which stillconstitutes
the main obstacle in MS therapeutic studies due to the
complexityoftheneuronalnetwork.Nevertheless,increasing
evidence supports that the resident immune cells, microglia,
functioning as a bridge between the CNS and immune
systems, are critical for MS pathogenesis. Regulation of mi-
croglial activation may become a new promising target for
therapy [22–25]. In this review, we discuss functions of mi-
croglia in MS, EAE and other experimental studies and
review evidence implicating the critical roles of microglia in
the complicated neural-immune networks.
2.Microglia inMS
Microglia derive from myeloid origin and acquire properties
including cytokine production, phagocytosis, and antigen
presentation, which allow microglia to play critical roles in
both innate and adaptive immunity [23, 26]. Resting micro-
gliahavearamiﬁed morphologyandcanactivelysurveytheir
surroundings sending out long processes to sense events oc-
curring in their microenvironment [23]. Upon activation,
microglia alter their morphology from a ramiﬁed state to
assume an amoeboid shape [27]. They change expression
levels of cytokines, chemokines, and surface molecules pro-
duced to respond to injury in the CNS [23]. It has been
shown that microglia activation is an early event in diﬀerent
disease models [9, 23, 28]. Depending on their unique func-
tionsdiﬀerentfromotherresidentcellsintheCNS,microglia
inevitably play an essential role in MS.
2.1. Microglia Are Required for Pathogenesis. Microglial acti-
vation was observedin bothactive demyelinating lesionsand
inﬂammatory nondemyelinating areas of MS brain and it
persisted for the whole course of the disease [29, 30]. Acti-
vated microglia were found to be attached to half-damaged
myelin sheaths [18]. Activated microglia in the active demy-
elinating areas were immunopositive for intracellular MBP
[31]. Marik et al. showed that microglia became activated
before demyelination was visualized and measurable [32].
This ﬁnding was consistent with studies using PET imaging
showing that microglia activation was evident in the normal
appearing white matter (NAWM), the tissue area devoid
of leukocyte inﬁltration, demyelination, or BBB disruption
[6]. Taken together, microglia activation during MS may be
involved in the development and expansion of the disease.
To clarify the roles of microglia activation in the patho-
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CD11b-HSVTK mice, in which herpes simplex virus thymi-
dine kinase expression was driven by the monocyte/macro-
phage/microglia CD11b promoter, with the intention to
deplete microglia activation during the disease. When
these CD11b-HSVTK animals are treated with ganciclovir
(GCV), all the actively proliferating cells that express the
transgene (macrophages, monocytes, and microglia) die.
Microglia “paralysis” (asdescribedby theauthors),mediated
by ganciclovir (GCV) application, resulted in attenua-
tion of disease severity, inﬂammation, and demyelination
[24]. Other studies using either the macrophage/microglia
inhibitory factor MIF (the tripeptide TKP) or minocycline
to inhibit microglia activation also showed ameliorated EAE
symptoms [22, 33, 34]. Therefore, microglia activation is a
necessary component in MS pathogenesis, and inhibition
of microglia activation appears to be beneﬁcial for disease
progression.
However, these results do not necessarily mean that acti-
vated microglia only contribute adversely to the disease.
Studies showed that the functions of activated microglia in
MS were complex and could lead to both beneﬁcial and
detrimentaloutcomesdependingontheformandthetiming
of activation [22, 29, 34, 35]. Here, microglial functions
in MS will be discussed in detail examining three aspects:
antigen presentation, cytokine release, and phagocytosis.
2.2. Antigen Presentation. During MS and EAE, T helper
(Th) cells are key mediators of the disease. In MS, Th1 and
Th17 are shown to be the main pathogenic T cells as they
promote BBB disruption, demyelination, and neurodegener-
ation [36, 37]. Anti-inﬂammatory Th2 and regulatory T cells
(Treg) normally protect against autoimmunity by inducing
tolerance of self-antigens, but their functions are impaired
during early disease [4].
Antigen presentation is a critical process for T cell activa-
tion and modulation of their function. Antigens presented
via the major histocompatibility complex (MHC-class I
and MHC-class II) on the APCs are required to initiate
CD8 and CD4 T cell activation. The co-stimulatory signals
betweenCD80,CD86,andCD40onAPCsandCD28,CTLA-
4, and CD40L on T cells are essential for full T cell acti-
vation. Without such costimulatory signaling, MHC-TCR
(T cell receptor) binding can lead to T cell death [1, 4,
13, 38]. Dendritic cells (DCs), the classically established
APCs, take the responsibility to initiate/prime na¨ ıve T cell
activation [13, 39–42]. It has been reported that microglia
only acquire the ability of antigen presentation upon acti-
vation, and that activated microglia favor the reactivation
of primed T cells and regulate their diﬀerentiation [36, 40,
41].
In the MS brain, activated microglia were shown to accu-
mulate in all plaque regions express MHC-class II molecules
and to be MBP-positive [31, 43, 44], suggesting that acti-
vated microglia in MS may also regulate T cell functions
and lesion formation. Studies using culture systems and
animal models further conﬁrmed this observation and elu-
cidated possible mechanisms. In vitro experiments showed
that microglia gave rise to DCs after stimulation by the
growth factor Granulocyte-macrophage colony-stimulating
factor (GM-CSF) [41]. Coculture of microglia with IFNγ+
Th1 cells and IFNγ+IL-17+ Th1/Th17 cells increased the
expression of MHC class II, CD40, CD80, and CD86 on
microglia. Moreover, the presence of microglia resulted in
signiﬁcant increase of IL-1β,T N F - α, and IL-6 expression in
Th1/Th17 cultures, which further promoted the diﬀerenti-
ation of proinﬂammatory Th cells. However, microglia/Th1
cocultures did not signiﬁcantly aﬀect cytokine release, sug-
gesting that microglia may have diﬀerent regulatory eﬀects
on Th1 and Th17 cells [36].
In vivo,upregulationofMHCclassIandII,CD40,CD80,
and CD86 expression on activated microglia was observed
[36, 38, 45, 46]. During EAE, the majority of activated
microglia express higher levels of MHC molecules at all
stages (initiation, peak, and recovery), and their expression
correlates with disease progression and T cell inﬁltration
[36, 47]. It is well accepted that there is an upregulation
of the co-stimulatory molecules CD80, CD86, and CD40
on the microglial surface, but the timing and intensity of
this increased expression depend on the type of stimula-
tion and microglial markers used. Both CD80 and CD86
are expressed on the surface of MHCII+F4/80+ microglia/
macrophages in TMEV virus infected mice [45]. Murphy
et al. showed in an EAE model that increased expression
of co-stimulatory molecules on CD11+CD45high activated
microglia/macrophages correlated with EAE progression
[36]. However, Almonlda et al. showed that only a subset of
tomato lectin+ microglia/macrophages expressed CD86at all
stages, whereas, Iba-1+ microglia expressed CD86 only at the
recoverystageofEAE,while therewas noCD80expression at
any time point [47]. Due to lack of co-stimulatory signaling
on some cells, it is possible that activated microglia may
induce apoptosis of T cells.
In addition to the classically activating co-stimulatory
pathways, the inhibitory signaling of B7 homolog 1 (B7-
H1)/programmed death receptor-1 (PD-1) between micro-
glia and T cells is another key regulator of T cell functions
[13, 46, 48]. In acute MS lesion areas, activated microglia
were B7-H1 positive [49]. Moreover, B7-H1 expression in
microglia was higher than that in astrocytes and splenocytes
[50]. In animal models, B7-H1−/− mice or mice receiving
anti-B7-H1 treatment showed worse disease symptoms,
accompanied by increased demyelination and inﬂammation
in the CNS [46, 51].
Although they present antigens to T cells, activated mi-
croglia do not function as mature DCs (mDCs): a high
microglia/T cell ratio was required to induce proliferation
of na¨ ıve T cells [52]. Activated microglia expressed only low
levels of co-stimulatory molecules compared with mDCs
during EAE [38, 47]. It has also been shown that activated
microglia do not express fascin, a marker for DC matura-
tion, suggesting that microglia may function as immature
DCs to induce tolerance of T cells to antigens [47, 53,
54]. Collectively, microglia present antigen to T cells and
regulate T cell functions throughout the whole process of
MS disease. The interaction between microglia and T cells
does not just promote T cell activation and diﬀerentiation,
but also regulates inhibition through presenting inhibitory
signaling.4 Neurology Research International
2.3. Cytokine and Other Mediators. Cytokine release from
activated microglia has been extensively studied both in
vivo and in vitro using diﬀerent types of stimulation [55–
57]. TMEV infection, lipopolysaccharide (LPS), and IFN-γ
induce microglial expression of proinﬂammatory cytokines
and mediators, such as nitric oxide (NO) and TNF-α,t o
promote inﬂammation and antigen presentation. These
“classically activated” microglia are deﬁned as M1 microglia.
The majority of activated microglia early in MS and animal
models were M1 microglia. On the other hand, IL-4 and IL-
13 promote “alternatively activated” microglia (M2) diﬀer-
entiation. M2 microglia produce anti-inﬂammatory medi-
ators including IL-4 and IL-10 to induce tissue repair [23,
28, 56]. M2 microglia (CD163+) were observed throughout
the acute active lesions and the hypercellular rim of chronic
active lesion in MS patients [31]. Studies from EAE and
other models indicated that M1 and M2 microglia may have
distinct functions in MS [29, 58].
2.3.1. Microglia and Neurons. Glutamate excitotoxicity-in-
duced neurodegeneration has been described in MS and
observed in the EAE model [5, 8]. EAE animals showed
abnormal synaptic transmission with increased spontanous
excitatory postsynaptic potential (sEPSP) frequency and a
slower decay phase. Application of TNF-α or M1 microglia
tobrainsliceculturesreproducedthesedefects.However,M1
microglia treated with anti-TNF receptor (TNFR) abolished
synaptic defects suggesting that microglia regulate synaptic
transmission via TNF-αsignaling [5].Furthermore,medium
from M1 microglia signiﬁcantly decreased cortical neuronal
survival, whereas M2-derived medium did not have any
eﬀect[28].Dorsal root ganglia (DRG)neuronsculturedwith
M1 medium extended short and highly branched neurites,
but those cultured with M2 medium showed bipolar mor-
phology with longer processes. In addition, M2 microglia,
together with Chondroitinase ABC (ChABC), signiﬁcantly
increased axon growth on inhibitory substrates of Chon-
droitin sulfate proteoglycan (CSPG) compared with M1
[28].
2.3.2. Microglia and Oligodendrocyte/Oligogenesis. The
mechanisms by which activated microglia promote demyeli-
nation and impair remyelination possibly include both
induction of OL death and attenuation of oligogenesis. It
has been reported that activated microglia phagocytosed
myelin debris in MS and EAE [58]. Activated microglia in
MS were MBP-positive, indicative of microglial phagocytosis
of oligodendrocyte components; in addition, medium from
M1 microglia signiﬁcantly decreased survival rate of OLs in
culture [31, 59].
It is not entirely clear how microglia aﬀect oligogenesis
per se, but evidence has indicated that microglia activation
impaired the function of both neural stem cells (NSCs;
indirect eﬀect on oligodendrocyte precursor cells, OPCs,
since OPCs derive from NSCs), and OPCs (direct eﬀect).
Enlargement of subventricular zone (SVZ) and increased
proliferationofendogenousNSCswereobservedduringEAE
and local demyelination models [34, 60]. However, temporal
studiesindicatedthatresponses ofNSCswere transientatthe
acute stage and completely lost in the chronic stages [34].
Moreover, increased NG2+ OPCs clustered in the SVZ but
d i dn o tm i g r a t ei n t ot h ew h i t em a t t e r[ 60]. Experimental
evidence showed that the proinﬂammatory microenviron-
ment by M1 microglia contributed to the insuﬃcient repair.
Activated microglia were observed in the NSC niche in
contact with the NSCs [60]. Medium from M1 microglia
decreased the number of OPCs and mature OLs diﬀeren-
tiated from NSCs. TNF-α inhibition dramatically down-
regulated this eﬀect, suggesting that TNF-α primarily medi-
atedthe detrimentaleﬀectofM1microglia [35,59,61].Inhi-
bition of microglia by minocycline signiﬁcantly increased
proliferation and diﬀerentiation of OPCs in EAE [34].
Therefore, although endogenous NSCs/OPCs do respond
during the disease, their reactivity is not suﬃcient to over-
come inhibition from M1 microglia or to promote eﬃcient
oligogenesis.
Due to the deﬁcits of endogenous NSC/OPCs functions
in MS,transplantation ofNSCshasbeenadoptedtopromote
recovery. Several studies showed that NSC transplantation
dramatically attenuated disease severity, promoted remyeli-
nation, and inhibited inﬂammation [62–64]. Like endoge-
nous NSCs, transplanted NSCs also expressed receptors
for cytokine and chemokines; therefore, their migration
and functions were under regulation by the inﬂammatory
environment [65, 66]. The presence of an anti-inﬂammatory
environment, induced by IL-10, signiﬁcantly enhanced adult
NSC-induced functional recovery from EAE [65]. However,
transplanted NSCs can also regulate immune cell functions
in a dose-dependent manner [63, 67, 68]. In vitro cultured
neurospheres signiﬁcantly inhibited proliferation of MOG-
speciﬁc lymph node cells and switched their cytokine proﬁle
from Th1 to Th2 [63]. Interestingly, there is no evidence
supporting the notion that transplanted NSCs may have
functions that are not present in the endogenous NSCs,
suggesting that numbers or intensity of NSCs during the
disease might be a critical factor determining the outcomes.
Even though a proinﬂammatory environment still inhibits
functions of transplanted NSCs, because a large number of
NSCcellsaretransplanted,apercentageofthesetransplanted
NSCs can still survive after “dealing with” and surviving the
attacks of inﬂammatory cells. It would then be these remain-
ing NSCs that migrate and function to promote recovery. If
this is the case, then the hypothesis that promoting a balance
or homeostasis between CNS responses and immune insults
is fundamental for disease recovery.
2.3.3. Microglia and T Cells. In addition to the regulation
of T cell activation via antigen presentation (discussed in
Section2.2),activatedmicrogliacoulddirectTcellmigration
and diﬀerentiation through modulation of the chemokine/
cytokine environment.
Chemokines released from activated microglia contrib-
ute to leukocytes migration/inﬁltration into the CNS. In
vitro, TMEV and IL-17A stimulated microglia expressed
CCL2, CXCL3, and CCL12, which had been shown to pro-
mote the migration/inﬁltration of chemokine receptor-
expressing leukocytes into the brain [69–71]. In MS plaquesNeurology Research International 5
Table 1: Functions and outcomes of microglial activation during EAE/MS.
Function Mediator Timing of expression Expression level Outcomes
Antigen
Presentation
Activating
MHC class I, MHC
class II
All stages (initiation,
peak and recovery)
Signiﬁcantly
increased
Present antigen, initiate
Tc e l la c t i v a t i o n ;I n d u c e
apoptosis without
co-stimulatory
molecules
CD80, CD86, CD40, Depends on cell
markers chosen
Increased, but lower
than DCs
Fully activate T cell with
MHC molecules
Inhibitory B1-H7 Not examined Increased Tc e l la c t i v a t i o n
inhibition
Cytokine/
chemokine release
Proinﬂammatory
(M1)
IL-1β,T N F - α,I L - 6 ,
NO, IFN-γ,I L - 1 2
High at onset,
sustained at all stages
(initiation,peak and
recovery)
Dramatically
increased, dominant
Induce synaptic deﬁcits;
death of neurons and
OLs;
Induce Th1 and Th17
diﬀerentiation;
Induce disfunction of
NSCs/OPCs
Anti-inﬂammatory
(M2) IL-4, IL-10, TGF-β
Low at onset,
increased at later time
points
Increased, lower than
M1
Promote growth of long
dendrites;
Induce Th2 and Treg
diﬀerentiation;
Increase proliferation
and diﬀerentiation of
NSCs/OPCs
Chemokines CCL2, CXCL3,
CCL12, CCL4, CCL5 Varies Increased Regulate migration of T
cells, NSCs and OPCs
Phagocytosis
Activating CR3, SRA, FcγR,
TREM2 Not examined Increased
Facilitate recognition of
myelin, remove myelin
debris
Inhibitory SIRPα Not examined Decreased
Downregulate
phagocytosis, induce
self-tolerance
and TMEV-IDD, increased expression of CCL2, CCL4, and
CCL5 was observed in activated microglia [72–75]. Inhi-
bition of microglial activation by the tripeptide MIF/TKP
signiﬁcantly decreased T cell numbers in the CNS [22].
Activated microglia express cytokines required for T cell
diﬀerentiation. M1 microglia stimulated by TMEV and LPS
produced high levels of TNF-α, IL-6, and IL-12, which
promoted the diﬀerentiation and expansion of Th1 and/or
Th17 cells [13, 39]. Coculture of microglia and Th1/Th17
cellsincreased IL-1βandIL-6release, which were responsible
for further expansion of Th1/Th17 cells [36]. M2 microglia
expressing IL-4and IL-10wererequiredforTh2 andTreg dif-
ferentiation [4]. TGF-β released from M2 directly promoted
Treg diﬀerentiation and could regulate Th17 functions
indirectly through inhibition of Th1 and Th2 diﬀerentiation
[4, 76]. To conclude, M1 microglia promote T cell diﬀeren-
tiation toward Th1 and Th17 fates and synergistically induce
demyelination and neurodegeneration. On the other hand,
M2 microglia, together with anti-inﬂammatory T cells (Th2
and Treg), protect the system from damage and promote
recovery.
2.3.4. Timing and Intensity of Microglia Activation. Both M1
proinﬂammatory microglia and M2 anti-inﬂammatory mi-
croglia contribute to MS progression, but M1 microglia are
dominant early and during the whole process. This M1
prevalence is induced by diﬀerences in timing and intensity
of M1 and M2 microglial activation. M1 microglia are ob-
served in the CNS since the onset of the EAE and are
sustained through the whole process. However, a delayed
M2 diﬀerentiation has been described, accompanied by
persisting low numbers of M2 microglia during EAE, which
resultedinanimbalancebetweenthetwomicroglialsubtypes
and high M1/M2 ratio [29, 36]. Because of this delayed and
lowerM2diﬀerentiation,eventhoughtheM2populationhas
ap r o t e c t i v ee ﬀect, it still cannot overcome the detrimental
eﬀects of the M1 population. To promote recovery through
regulating microglia functions, changing the M1/M2 ratio
would be a key point. In line with this, injection of IL-
10/IL-13 activated M2 macrophages/monocytes signiﬁcantly
inhibited microglial activation and suppressed EAE symp-
toms presumably through rebalancing the M1/M2 ratio
[29]. Similarly, the beneﬁcial eﬀects of minocycline on EAE6 Neurology Research International
symptoms mightbeduetoitsbiasedinhibitionofM1micro-
glia [34, 59, 77].
Nonetheless, balancing the M1/M2 ratio does not mean
that total suppression of the M1 population is good for the
disease, since M1 microglia are not always bad. Butovsky et
al.showedthatmoderateM1microgliaactivationinducedby
IFN-γ couldincrease neurogenesis and oligogenesis, whereas
excessive activation inhibited these eﬀects [35, 61]. It is
also reported that controlled microglial activation and T
cell inﬁltration promoted recovery from optic nerve injury
[78]. Therefore, M1 microglia could be beneﬁcial for tissue
recovery if the extent of their activation is controlled within
a well-deﬁned range.
2.3.5. Phagocytosis. Phagocytosis of myelin debris by acti-
vated microglia was observed in MS lesions and it was an
essential response to promote regeneration [25, 58]. Phago-
cytic ability of microglia is mediated by interactions between
myelinligandsandreceptorsonmicroglia.Myelinstimulated
microglial activation through the binding of complement
receptor 3 (CR3), scavenger receptor AI/II (SRA), and Fcγ
receptor (FcγR), which then induced further activation and
phagocytosis[79–81].Ontheotherhand, signalingpathways
like myelin-CD47 binding to signal regulatory protein-α
(SIRPα) can down regulate microglial phagocytosis [82].
Such inhibitory pathways were originally thought to induce
self-tolerance by protecting healthy cells from attacks by
phagocytes. However, the expression of CD47 was reported
to be signiﬁcantly decreased in MS lesions, suggesting the
onset ofuncontrolled phagocytosisby microglia [19].There-
fore, although phagocytosis of myelin debris is beneﬁcial
for recovery, its impact on disease progression is still under
debate.
The inﬂammatory environment is a keyregulator for mi-
crogliaphagocyticfunction.Applicationofproinﬂammatory
cytokines reduced phagocytosis by macrophages/microglia
[83]. Activated microglia dramatically increased expression
of the microglial triggering receptor expressed on myeloid
cells 2 (TREM2) during EAE [84, 85]. Studies showed
that TREM2 stimulated phagocytosis in vitro and promoted
an anti-inﬂammatory state in EAE [84, 86]. Inhibition of
TREM2 resulted in exacerbated EAE symptoms [87]. Fur-
thermore, pathways mediating microglial phagocytosis, as
mentioned above, including CR3/MAC-1 and CD47/SIRPα,
were not restricted to regulating phagocytosis, but also had
broad eﬀects on microglial activation and migration [18].
It is suggested then that phagocytic function of microglia
is tightly correlated with and under control of the status
of microglial activation in MS. Insuﬃcient myelin clean-up
may be due to blockade of phagocytosis by an unbalanced
M1/M2 ratio.
3.Conclusions
Microglial activation is not just a hallmark of MS, but is re-
quiredfordisease pathogenesis.Activatedmicroglia diﬀeren-
tiate into M1 and M2 microglia and contribute to both pro-
tective and detrimental aspects of the inﬂammatory process
through antigen presentation, cytokine release, and phago-
cytosis (Table 1). Regulating microglial functions could both
aﬀect the level of inﬂammatory insults and change local
responses from neural cells. However, beneﬁcial eﬀects will
only be brought when microglial activation is well-deﬁned
in time, intensity, and direction of diﬀerentiation, which
are still unclear. Further studies are required to clarify and
precisely determine these parameters to fully understand the
functions of microglia in MS.
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